-+ 0.00%
-+ 0.00%
-+ 0.00%

Hansoh Pharma says NMPA grants priority review for HS-20093 in small cell lung cancer

PUBT·09/11/2026 08:31:32
Listen to the news
Hansoh Pharma says NMPA grants priority review for HS-20093 in small cell lung cancer
  • Hansoh’s HS-20093 (risvutatug rezetecan) for small cell lung cancer entered China NMPA priority review on Aug. 21, 2026.
  • Filing targets patients whose disease progressed following prior platinum-based chemotherapy.
  • Submission supported by positive results from the Phase III ARTEMIS-008 trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260911-12328908), on September 11, 2026, and is solely responsible for the information contained therein.